Dr. David Hung resigns as CEO and continues as scientific advisor to Roivant family of companies Dr. Pavan Cheruvu appointed as CEO of Axovant Dr. Roger Jeffs , former President and co-CEO of United Therapeutics , and George Bickerstaff , former CFO of Novartis Pharma, join board of directors

BASEL, Switzerland , Jan. 09, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced a correction to the data related to the Company’s investigational drug nelotanserin previously reported in its January 8, 2018 press release. In the results of the pilot Phase 2 Visual

-- Intepirdine Program to be Discontinued Based on MINDSET, HEADWAY,  and Gait and Balance Study Results -- -- Company to Advance to Larger Confirmatory Nelotanserin DLB Study  Focused on Motor Function and Psychosis -- -- Conference Call Today at 8:00 a.m. EST -- BASEL, Switzerland , Jan.

BASEL, Switzerland , Jan. 05, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that its Chief Executive Officer David Hung , MD, will be presenting at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9 th at 10:00 a.m. PST at the Westin St.

BASEL, Switzerland , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Axovant Sciences (Nasdaq:AXON) today announced financial results for its second fiscal quarter and first half ended September 30, 2017 , and provided an update on its clinical programs. Key Highlights Strong balance sheet with $235.4 million of

--Conference call today at 8:00 a.m. EDT-- BASEL, Switzerland , Sept. 26, 2017 /PRNewswire/ --  Axovant Sciences (NASDAQ: AXON) today announced that the Phase 3 MINDSET clinical trial of its investigational drug intepirdine in patients with mild to moderate Alzheimer's disease (AD) who were

BASEL, Switzerland , Sept. 6, 2017 /PRNewswire/ --  Axovant Sciences (NYSE: AXON) today announced upcoming presentations by David Hung , M.D., chief executive officer of Axovant, on September 6, 2017 at 12:50 p.m. ET at the Baird 2017 Global Healthcare Conference, and on September 12, 2017 at 10:35

-- Ticker Symbol to Remain AXON -- BASEL, Switzerland , Aug. 21, 2017 /PRNewswire/ --  Axovant Sciences (NYSE: AXON) today announced that it will voluntarily move its stock exchange listing from the New York Stock Exchange to the Nasdaq Global Select Market.

BASEL, Switzerland , Aug. 7, 2017 /PRNewswire/ -- Axovant Sciences (NYSE:   AXON ) today announced financial results for the three months ended June 30, 2017 as well as general business updates. Key Highlights   Strong balance sheet with $297.9 million of cash as of June 30, 2017 supports

BASEL, Switzerland , July 19, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON) today announced new data from a preclinical study which suggests that intepirdine may have neuroprotective properties against vascular injury and neuronal metabolic dysfunction (poster P4-588).